# **Special Issue**

# Advanced Research of Gut Microbiota in Health and Diseases—2nd Edition

# Message from the Guest Editors

The study of the human microbiota is proving to be of fundamental importance in understanding the development and pathogenesis of numerous pathological conditions, not only those of a gastroenterological nature. Numerous pieces of evidence highlight a connection between the dysregulation of the gut microbiota and the occurrence of numerous pathological conditions such as inflammatory and metabolic disorders and degenerative and autoimmune diseases. More and more studies are highlighting the correlation between the gut microbiota and disease occurrence, so it is of paramount importance to stay up-to-date with the latest evidence. This Special Issue titled "Advanced research of gut microbiota in health and diseases" invites contributions concerning the connection between alterations in the microbiota and the development of diseases affecting the digestive system and beyond. Authors are also invited to participate with papers regarding the latest evidence on the state of the microbiota in the healthy individual, another of the most interesting and evolving topics.

- microbiota
- dysbiosis
- gut microbiome
- gut

## **Guest Editors**

Dr. Andrea Piccioni

Emergency Medicine Department, University Polyclinic Foundation A. Gemelli, IRCCS (Scientific Institute for Hospitalization and Treatment), 00168 Rome, Italy

Dr. Federico Rosa

Department of Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy

# Deadline for manuscript submissions

28 February 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/202689

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





# **About the Journal**

# Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).